期刊
BIOTECHNOLOGY JOURNAL
卷 15, 期 9, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.202000069
关键词
Ebola virus; epitope mapping; human sera; neutralizing antibodies; recombinant vesicular stomatitis virus-Zaire ebolavirus
资金
- German Federal Ministry of Education and Research [BMBF] [13XP5050A]
- MPG-FhG cooperation [Glyco3Display]
- Max Planck Society
- Wellcome Trust
- German Center for Infection Research (DZIF) (TTU emerging infections)
- German National Department for Education and Research (BMBF)
- German Ministry of Health (BMG)
The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti-EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Here, the analysis of serum samples from an EBOV vaccine trial with the recombinant vesicular stomatitis virus-Zaire ebolavirus (rVSV-ZEBOV) and an Ebola virus disease survivor, using high-density peptide arrays, is presented. In this proof-of-principle study, distinct IgG and IgM antibodies binding to different epitopes of EBOV GP is detected: By mapping the whole GP as overlapping peptide fragments, new epitopes and confirmed epitopes from the literature are found. Furthermore, the highly selective binding epitope of a neutralizing monoclonal anti-EBOV GP antibody could be validated. This shows that peptide arrays can be a valuable tool to study the humoral immune response to vaccines in patients and to support Ebola vaccine development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据